Immunotherapy was long considered as an attractive modality in the treatment of lung cancer. However, clinical successes were hampered by the inability to achieve potent activation of the antitumor immune system and effectively overcome the immune suppressive environment associated with lung cancer. Recent advances in cancer immunotherapy demonstrate that these limitations can be surmounted. In...

As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a clinically beneficial alternative to conventional therapies for a variety of malignancies. Characterized by broad clinical activity, durable response rates, distinct side effects, and uniq...

Cancer immunotherapy is at dawn of the Renaissance after the Medieval Dark Ages. Recent advances of understanding tumor immunology and molecular drug development are leading us to the epoch of cancer immunotherapy. Some types of immunotherapy have shown to provide survival benefit for patients with solid tumors such as malignant melanoma, renal cell carcinoma, or non-small cell lung cancer. Sev...

Hepatocellular carcinoma (HCC) is considered a classic inflammation-associated tumor that usually originates from chronic hepatitis, where an intense and inflammatory response leads to the accumulation of mutations eventually carcinogenesis under conditions persistent liver injury. In recent years, immunotherapy for HCC has continued evolve, as naturally filled with large variety immune cells, ...

The 22nd annual Cancer Research Institute (CRI) International Immunotherapy Symposiumwasheld fromOctober 5–8, 2014, in New York City. Titled "Cancer Immunotherapy: Out of the Gate," the symposiumbeganwith a Cancer Immunotherapy Consortium satellite meeting focused on issues in immunotherapy drug development, followed by five speaker sessions and a poster session devoted to basic and clinical ca...

Cancer was the second leading cause of death globally in 2018. On other hand, immunotherapy is one most promising and effective therapies to fight against cancer. This area research has highly increased over last decade. Immunotherapy will modulate initiate an immune response. Hence, system body be more potent combating can utilize herbal products with low toxicity. In addition, usage also prov...

Cancer immunotherapy represents a very encouraging mode of treatment for cancer where one’s immune system is utilized to eliminate tumor cells. Wayne et al. explore inhibition DNA damage response (DDR) pathways with small molecule inhibitors as means prime cells response. These findings suggest that one-size-fits-all approach cannot be used when harnessing via DDR and genotoxic agents, which ar...

The prognosis for patients with ovarian cancer is still poor and more effective therapeutic modalities are needed. (Radio)immunotherapy using monoclonal antibodies (Mabs) could be one of these approaches. Here, we review the status of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The Pubmed database was searched for clinical trials investigating the effect of (radio)immun...

The effect of cancer immunotherapies is on the immune system and not directly on the tumour. The kinetics of immunotherapy are characterised by a cellular immune response followed by potential changes in tumour burden or patient survival. To adequately investigate immunotherapies in clinical trials, a new development paradigm including reconsideration of established end points addressing this b...